End-of-day quote
Shenzhen S.E.
23:00:00 15/05/2024 BST
|
5-day change
|
1st Jan Change
|
20.69
CNY
|
-0.77%
|
|
+0.63%
|
-4.70%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
9,134
|
17,038
|
16,825
|
8,880
|
7,555
|
7,116
|
-
|
Enterprise Value (EV)
1 |
9,134
|
17,038
|
16,825
|
8,880
|
7,555
|
7,116
|
7,116
|
P/E ratio
|
15.6
x
|
25.5
x
|
81.9
x
|
-75.1
x
|
271
x
|
26
x
|
22.5
x
|
Yield
|
-
|
0.53%
|
0.21%
|
-
|
0.23%
|
0.53%
|
1.06%
|
Capitalization / Revenue
|
4.33
x
|
6.58
x
|
6.61
x
|
3.33
x
|
2.99
x
|
2.45
x
|
2.12
x
|
EV / Revenue
|
4.33
x
|
6.58
x
|
6.61
x
|
3.33
x
|
2.99
x
|
2.45
x
|
2.12
x
|
EV / EBITDA
|
11.5
x
|
18.7
x
|
38.8
x
|
58
x
|
20.6
x
|
12
x
|
10.7
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
4.48
x
|
6.42
x
|
4.54
x
|
2.54
x
|
2.17
x
|
1.92
x
|
1.73
x
|
Nbr of stocks (in thousands)
|
328,031
|
328,002
|
347,977
|
347,977
|
347,977
|
343,927
|
-
|
Reference price
2 |
27.84
|
51.94
|
48.35
|
25.52
|
21.71
|
20.69
|
20.69
|
Announcement Date
|
23/04/20
|
19/04/21
|
21/04/22
|
26/04/23
|
25/04/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
2,111
|
2,587
|
2,545
|
2,667
|
2,527
|
2,908
|
3,352
|
EBITDA
1 |
792.6
|
912.5
|
434.1
|
153.1
|
366.1
|
595
|
665.5
|
EBIT
1 |
688.3
|
775.7
|
240.1
|
-101.8
|
70.75
|
321
|
373
|
Operating Margin
|
32.61%
|
29.98%
|
9.43%
|
-3.82%
|
2.8%
|
11.04%
|
11.13%
|
Earnings before Tax (EBT)
1 |
684.1
|
768.9
|
218.4
|
-110.5
|
71.92
|
319.3
|
370.7
|
Net income
1 |
585.7
|
667.1
|
204.7
|
-119
|
27.36
|
277
|
320.7
|
Net margin
|
27.75%
|
25.78%
|
8.04%
|
-4.46%
|
1.08%
|
9.53%
|
9.57%
|
EPS
2 |
1.789
|
2.033
|
0.5900
|
-0.3400
|
0.0800
|
0.7967
|
0.9200
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
0.2778
|
0.1000
|
-
|
0.0500
|
0.1100
|
0.2200
|
Announcement Date
|
23/04/20
|
19/04/21
|
21/04/22
|
26/04/23
|
25/04/24
|
-
|
-
|
Fiscal Period: December |
2023 S1
|
---|
Net sales
|
-
|
EBITDA
|
-
|
EBIT
|
-
|
Operating Margin
|
-
|
Earnings before Tax (EBT)
|
-
|
Net income
1 |
68.11
|
Net margin
|
-
|
EPS
2 |
0.2000
|
Dividend per Share
|
-
|
Announcement Date
|
28/08/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
33.7%
|
28.5%
|
5.65%
|
-3.29%
|
0.78%
|
7.33%
|
7.77%
|
ROA (Net income/ Total Assets)
|
-
|
17.3%
|
3.83%
|
-
|
-
|
3.9%
|
2.7%
|
Assets
1 |
-
|
3,865
|
5,345
|
-
|
-
|
7,103
|
11,877
|
Book Value Per Share
2 |
6.210
|
8.090
|
10.70
|
10.00
|
10.00
|
10.80
|
12.00
|
Cash Flow per Share
2 |
1.300
|
1.900
|
-0.7500
|
-0.1400
|
-0.1300
|
0.9200
|
1.540
|
Capex
1 |
353
|
505
|
736
|
523
|
313
|
103
|
154
|
Capex / Sales
|
16.74%
|
19.53%
|
28.9%
|
19.61%
|
12.39%
|
3.54%
|
4.6%
|
Announcement Date
|
23/04/20
|
19/04/21
|
21/04/22
|
26/04/23
|
25/04/24
|
-
|
-
|
Last Close Price
20.69
CNY Average target price
22.6
CNY Spread / Average Target +9.23% Consensus |
1st Jan change
|
Capi.
|
---|
| -4.70% | 993M | | +21.98% | 43.92B | | +24.56% | 23.09B | | +19.25% | 15.35B | | +14.03% | 13.61B | | +46.40% | 12.02B | | -10.14% | 7B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +13.88% | 5.6B |
Generic Pharmaceuticals
|